X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.biospace.com/article/releases/rexahn-pharmaceuticals-announces-expected-effectiveness-of-reverse-stock-split-and-merger-transaction-with-ocuphire-pharma/?s=79
https://www.biospace.com/article/releases/rexahn-and-ocuphire-enter-into-definitive-merger-agreement/?s=79
https://www.in-pharmatechnologist.com/Article/2019/04/18/Rexahn-licenses-pancreatic-cancer-drug-candidate-in-China
https://www.globenewswire.com/news-release/2019/04/16/1804668/0/en/Rexahn-and-BioSense-Global-Announce-Collaboration-and-License-Agreement-for-RX-3117-in-Greater-China.html
https://www.nasdaq.com/press-release/bioxcel-therapeutics-enhances-leadership-with-appointment-of-vikas-sharma-phd-as-vice-president-of-20180731-00676
https://trueindustrynews.com/global-renal-cell-cacinoma-drugs-market-overview-2018-rexahn-pharmaceuticalsbionomicscerulean-pharma-inccelldex-therapeuticstvax-biomedicaltracon-pharmaceuticals/
https://www.benzinga.com/analyst-ratings/analyst-color/18/07/12109801/pluristem-therapeutics-rexahn-pharma-are-biotech-winner
https://globenewswire.com/news-release/2018/05/15/1502499/0/en/Rexahn-Phase-2a-Combination-Study-of-RX-3117-and-Abraxane-in-First-line-Metastatic-Pancreatic-Cancer-Patients-Advances-to-Second-Stage.html
http://investors.rexahn.com/news-releases/news-release-details/rexahn-pharmaceuticals-present-two-upcoming-conferences
http://investors.rexahn.com/news-releases/news-release-details/rexahn-reports-data-ongoing-phase-2a-clinical-trial-rx-3117
Market Place
Share 
